Congress Asset Management Co. Reduces Stake in Zoetis Inc. $ZTS

Key Points

• Congress Asset Management cut its stake in Zoetis (ZTS) by 11.1% in Q4, selling 18,852 shares and ending the quarter with 151,522 shares worth about $19.07 million.
• Meanwhile, large institutions ramped up positions—Norges Bank and Diamond Hill bought new large stakes and Nordea and Arrowstreet materially increased holdings—leaving institutional ownership at approximately 92.8%.
• Zoetis recently beat Q results (EPS $1.48 vs. $1.40 expected), reported revenue up 3% year-over-year, set FY2026 guidance of $7.00–$7.10 EPS, and declared a quarterly dividend of $0.53 ($2.12 annual, ~1.8% yield).

Congress Asset Management Co. lowered its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 151,522 shares of the company's stock after selling 18,852 shares during the quarter. Congress Asset Management Co.'s holdings in Zoetis were worth $19,065,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Norges Bank purchased a new stake in shares of Zoetis in the second quarter worth about $809,491,000. Diamond Hill Capital Management Inc. bought a new position in shares of Zoetis in the third quarter valued at approximately $394,010,000. Nordea Investment Management AB grew its stake in Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Zoetis by 83.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock worth $394,746,000 after acquiring an additional 1,227,085 shares during the period. Finally, Corient Private Wealth LLC increased its holdings in Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company's stock worth $400,619,000 after acquiring an additional 1,191,840 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 0.6%

Shares of Zoetis stock opened at $115.94 on Wednesday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $113.30 and a 1 year high of $172.23. The firm has a market cap of $48.94 billion, a PE ratio of 19.26, a PEG ratio of 1.76 and a beta of 0.95. The company has a 50 day simple moving average of $123.97 and a two-hundred day simple moving average of $129.76.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio is currently 35.22%.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. BTIG Research reissued a "buy" rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Piper Sandler reiterated a "neutral" rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. William Blair reissued an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, The Goldman Sachs Group upgraded Zoetis to a "buy" rating in a research report on Monday, December 15th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $152.91.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.